Baili Tianheng's Iza‑bren (iza‑bren), the world's first and only approved EGFR×HER3 bispecific antibody‑drug conjugate (ADC), has been included in the 2026 National Basic Medical Insurance, Work-Related Injury and Maternity Insurance Drug Catalogue following national reimbursement negotiations. Benefiting from this year's new 'pre‑filing' mechanism, Iza‑bren achieved reimbursement inclusion in its first year on market.